Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
radiopharmaceuticals
Biotech
Sanofi $110M radioligand therapy hits main goal in ph. 2 trial
Sanofi’s bet on a radioligand therapy seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints of a phase 2 study.
James Waldron
Oct 8, 2025 6:25am
Lantheus taps GE HealthCare to sell its PSMA PET tracer in Japan
Sep 24, 2025 11:30am
GE HealthCare considering stake sale in China division: report
Sep 18, 2025 2:30pm
FDA flags review of Telix's radiodiagnostic for kidney cancer
Aug 28, 2025 11:20am
Radiopharma biotech Artbio paints path to clinic with $132M
Jul 29, 2025 7:30am
Nuclidium raises $99M for copper-based radiopharma pipeline
Jul 10, 2025 5:04am
